Literature DB >> 16803681

Overexpression of glyoxalase system enzymes in human kidney tumor.

Cinzia Antognelli1, Francesca Baldracchini, Vincenzo Nicola Talesa, Elisabetta Costantini, Alessandro Zucchi, Ettore Mearini.   

Abstract

PURPOSE: The purpose of this study was to investigate the messenger RNA expression and activity of glyoxalase I and glyoxalase II enzymes in a human renal carcinoma (clear cell adenocarcinoma) and in pair-matched normal tissue. PATIENTS AND METHODS: Tumor and nontumor pair-matched specimens from the same organ were collected during radical nephrectomy from a group of 12 patients of both sexes. The mean age of the patients was 52.3 years (range, 50-60 years), and none of them had previously undergone neoadjuvant therapy. Gene expression and activity were measured by ribonuclease protection assay and current spectrophotometric methods, respectively. Intracellular levels of methylglyoxal were detected by high performance liquid chromatography.
RESULTS: A significant increase in the transcription levels of both glyoxalase I (about ninefold) and glyoxalase II (about threefold) was observed, compared with the pair-matched noncancerous tissues. Glyoxalase I activity was also higher in the pathological samples (about 2.5-fold) compared with the control samples and correlated with a significant decrease (about twofold) in methylglyoxal concentrations. At variance, glyoxalase II activity was significantly lower in pathological tissues than in the normal ones. DISCUSSION: Our findings suggest a possible role of the glyoxalase system enzymes in the chemoresistance displayed by the kidney tumor. In fact, such a refractory behavior involves a decrease in the methylglyoxal level, a potent apoptosis activator. In addition, glyoxalase II activity decrease in the adenocarcinoma tissue suggests a likely role of the intermediate S-D-lactoylglutathione by supplying energy in actively proliferating cells. Finally, we point out a possible use of glyoxalase I inhibitors as anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16803681     DOI: 10.1097/00130404-200605000-00011

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  14 in total

1.  Polymorphisms of the receptor for advanced glycation end-products and glyoxalase I in patients with renal cancer.

Authors:  Matúš Chocholatý; Marie Jáchymová; Marek Schmidt; Klára Havlová; Anna Křepelová; Tomáš Zima; Marko Babjuk; Marta Kalousová
Journal:  Tumour Biol       Date:  2014-11-19

2.  Low red blood cell levels of deglycating enzymes in colorectal cancer patients.

Authors:  Maria Notarnicola; Maria Gabriella Caruso; Valeria Tutino; Vito Guerra; Giovanni Misciagna
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

3.  Arabidopsis thaliana GLX2-1 contains a dinuclear metal binding site, but is not a glyoxalase 2.

Authors:  Pattraranee Limphong; Michael W Crowder; Brian Bennett; Christopher A Makaroff
Journal:  Biochem J       Date:  2009-01-01       Impact factor: 3.857

4.  The effect of electroaucpuncture for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced proteomic changes in the mouse striatum.

Authors:  Seung-Tae Kim; Woongjoon Moon; Younbyoung Chae; Youn Jung Kim; Hyejung Lee; Hi-Joon Park
Journal:  J Physiol Sci       Date:  2009-09-18       Impact factor: 2.781

5.  Human glyoxalase II contains an Fe(II)Zn(II) center but is active as a mononuclear Zn(II) enzyme.

Authors:  Pattraranee Limphong; Ross M McKinney; Nicole E Adams; Brian Bennett; Christopher A Makaroff; Thusitha Gunasekera; Michael W Crowder
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

6.  The influence of glyoxalase 1 gene polymorphism on its expression at different stages of breast cancer in Egyptian women.

Authors:  Rehab S Abdul-Maksoud; Walid Sh Elsayed; Rasha S Elsayed
Journal:  Genes Cancer       Date:  2017-11

7.  Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2.

Authors:  Yuan Chen; Lei Fang; Jiali Zhang; Gefei Li; Mengni Ma; Changxi Li; Jianxin Lyu; Qing H Meng
Journal:  Int J Mol Sci       Date:  2017-03-09       Impact factor: 5.923

8.  Synergistic inhibition of colon cancer growth by the combination of methylglyoxal and silencing of glyoxalase I mediated by the STAT1 pathway.

Authors:  Yuan Chen; Lei Fang; Gefei Li; Jiali Zhang; Changxi Li; Mengni Ma; Chen Guan; Fumao Bai; Jianxin Lyu; Qing H Meng
Journal:  Oncotarget       Date:  2017-06-22

Review 9.  Glyoxalases in Urological Malignancies.

Authors:  Cinzia Antognelli; Vincenzo Nicola Talesa
Journal:  Int J Mol Sci       Date:  2018-01-31       Impact factor: 5.923

10.  Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models.

Authors:  Rahul Jandial; Josh Neman; Punnajit P Lim; Daniel Tamae; Claudia M Kowolik; Gerald E Wuenschell; Sarah C Shuck; Alexandra K Ciminera; Luis R De Jesus; Ching Ouyang; Mike Y Chen; John Termini
Journal:  Int J Mol Sci       Date:  2018-01-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.